All data are based on the daily closing price as of November 20, 2026
m
Medigen Vaccine Biologics
6547.TWO
1.19 USD
-0.10
-7.75%
Overview
Last close
1.19 usd
Market cap
392.21M usd
52 week high
2.16 usd
52 week low
1.09 usd
Target price
3.09 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
15.0608
Price/Book Value
3.2543
Enterprise Value
379.22M usd
EV/Revenue
14.5519
EV/EBITDA
95.262
Key financials
Revenue TTM
26.06M usd
Gross Profit TTM
15.79M usd
EBITDA TTM
2.73M usd
Earnings per Share
-0 usd
Dividend
N/A usd
Total assets
154.68M usd
Net debt
N/A usd
About
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. The company has a collaboration with Charles River Laboratories for the development of next-generation multivalent enterovirus vaccines, enhance global regulatory readiness, and support IND-enabling non-clinical studies. The company was incorporated in 2012 and is headquartered in Zhubei, Taiwan.